drugset / Trial / NCT03060343
Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)
Phase 0
Unknown
10 enrolled
Yu Fenglei
Hunan Yongren Medical Innovation Co. Ltd. · collabHunan Zhaotai Yongren Medical Innovation Co. Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
A single-center, open-label pilot study to determine the safety, tolerance and engraftment potential of zeushield cytotoxic T lymphocytes in subjects with PD-L1+ positive non-small cell lung cancer.
Timeline
- Start
- 2016-11-28
- Primary completion
- 2018-11-28
- Completion
- 2019-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zeushield Cytotoxic T Lymphocytes | Cell therapy | 100000 cells/kg | Other |
| Subject | Zeushield Cytotoxic T Lymphocytes | Cell therapy | 1e+06 cells/kg | Other |
| Subject | Zeushield Cytotoxic T Lymphocytes | Cell therapy | 1e+07 cells/kg | Other |